A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients with SF3B1 Mutation.
Liya Ma,Bin Liang,Huixian Hu,Wenli Yang,Shengyun Lin,Lihong Cao,Kongfei Li,Yuemin Kuang,Lihong Shou,Weimei Jin,Jianping Lan,Xingnong Ye,Jing Le,Huyi Lei,Jiaping Fu,Ying Lin,Wenhua Jiang,Zhiying Zheng,Songfu Jiang,Lijuan Fu,Chuanyong Su,XiuFeng Yin,Lixia Liu,Jiayue Qin,Jie Jin,Shenxian Qian,Guifang Ouyang,Hongyan Tong
DOI: https://doi.org/10.3389/fonc.2022.905490
IF: 4.7
2022-01-01
Frontiers in Oncology
Abstract:The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk following the revised International Prognostic Scoring System (IPSS-R). Although clonal hematopoiesis-associated mutations containing TET2, ASXL1 and DNMT3A were the most frequent co-mutant genes in these patients, RUNX1, EZH2, NF1 and KRAS/NRAS mutations had significant effects on overall survival (OS). Based on that we developed a risk scoring model as IPSS-R×0.4+RUNX1×1.1+EZH2×0.6+RAS×0.9+NF1×1.6. Patients were categorized into two subgroups: low-risk (L-R, score <= 1.4) group and high risk (H-R, score > 1.4) group. The 3-year OS for the L-R and H-R groups was 91.88% (95% CI, 83.27%-100%) and 38.14% (95% CI, 24.08%-60.40%), respectively (P<0.001). This proposed model distinctly outperformed the widely used IPSS-R. In summary, we constructed and validated a personalized prediction model of MDS patients with SF3B1 mutation that can better predict the survival of these patients.